Filing Details
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) filed a Form 8-K with the Securities and Exchange Commission on July 27, 2026, disclosing a material event.
8k filedNASDAQ:KYTX
Kyverna Therapeutics, Inc. (KYTX) Reports Material Event to SEC
Filing Details Kyverna Therapeutics, Inc. (NASDAQ:KYTX) filed a Form 8-K with the Securities and Exchange Commission on July 27, 2026, disclosing a material event. Market Context…
Market Context
Kyverna Therapeutics, Inc.'s stock currently trades at $7.92 with a market capitalization of $364.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Kyverna Therapeutics, Inc.'s stock.
All SEC filings for Kyverna Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View KYTX Stock Page
Frequently Asked Questions
Where can I read KYTX's SEC filings?
Browse all filings on our KYTX SEC filings page.
What types of SEC filings does Kyverna Therapeutics, Inc. file?
Public companies like Kyverna Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.